Leiomyosarcoma Drug Market Size, Share & Trends Analysis Forecast 2024-2031.
Leiomyosarcoma Drug Market Size, Share & Trends Analysis Forecast 2024-2031.
Blog Article
The global leiomyosarcoma drug market is expected to grow at a significant CAGR during the forecast period (2024-2031). Leiomyosarcoma is rare cancer that starts in the smooth muscle tissue of the body. Smooth muscle tissue can be found throughout the body, including the digestive system, urinary system, blood arteries, and uterus. The most common site of leiomyosarcoma is the abdomen or uterus. It begins as a proliferation of aberrant cells that quickly spreads to infect and destroy normal body tissue. Leiomyosarcoma signs and symptoms vary depending on where cancer begins. Pain, weight loss, and a developing lump or swelling that may be felt through the skin are all possible symptoms. Soft tissue sarcoma is a large category of tumors that arise in the tissues that link, support, and surround other body structures. A leiomyosarcoma is a form of soft tissue sarcoma. The chemotherapeutic drugs Adriamycin (Doxorubicin) and ifosfamide are presently used to treat leiomyosarcoma. Some people benefit from them, however, not everyone.
Get Sample Copy of this Report at
https://www.omrglobal.com/request-sample/leiomyosarcoma-drug-market
The increasing clinical trials associated with the leiomyosarcoma drugs is contributing to the growth of the market. As per the study conducted by Eli Lilly and MSK in 2016, Olaratumab is a targeted antibody medication that binds to and inhibits the PDGF-alpha receptor, which is present on the surface of cancer cells and in the tumor microenvironment (the area surrounding the tumor). Leiomyosarcoma was the most prevalent subtype seen in the study. In this ailment, the drug appeared to function exceptionally well. It was also remarkable that effectively it worked in people who had already tried other treatments. However, Eli Lilly, the manufacturer of olaratumab (Lartruvo), announced the drug's withdrawal from the market on April 25, 2019. This decision was made after the medicine failed to enhance survival in persons with soft tissue sarcoma in a phase III clinical trial. The business announced that it was launching a programme to ensure that patients who have benefited from the medicine can continue to use it.
Inquire for Discount on this Report at
https://www.omrglobal.com/report-customization/leiomyosarcoma-drug-market
The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, the first new anticancer treatments approved by the FDA in 2020 are for the treatment of two kinds of soft tissue sarcoma. The FDA authorized avapritinib (Ayvakit) for the treatment of certain patients with gastrointestinal stromal tumours (GIST) on January 9, 2020, and tazemetostat (Tazverik) for the treatment of certain patients with epithelioid sarcoma on January 23, 2020.
Competitive Landscape: Eli, Lilly & Co., and Advenchen Laboratories, LLC, among others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Leiomyosarcoma Drug Market Report by Segment
By Product Type
• AL-3818
• BGB-290
• C-21
• Others
By End-User
• Hospital
• Clinic
• Others
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 780-304-0404